Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455333 | 0.88 | CA12 (0.49) | CA1CA2CA12CA9LMNA | |
| SCHEMBL9194298 | 0.87 | TSHR (0.50) | CA1CA2CA12CA9LMNA | |
| SCHEMBL15067141 | 0.86 | CA1 (0.49) | CA1CA2CA12CA9LMNA | |
| SCHEMBL9193140 | 0.86 | ALDH1A1 (0.51) | CA1CA2CA12CA9LMNA | |
| Sulfuric Acid SCHEMBL9325271 | 0.83 | HIF1A (0.52) | CA1CA2CA12CA9MAPT | |
| SCHEMBL10714863 | 0.83 | CA1 (0.45) | CA1CA2CA12CA9LMNA | |
| SCHEMBL3654908 | 0.81 | LMNA (0.54) | CA1CA2CA12CA9LMNA | |
| SCHEMBL11224866 | 0.81 | ALDH1A1 (0.46) | LMNAMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL1578385 | 0.81 | CYP1A1 (0.50) | CA1CA2CA12CA9MAPT | |
| SCHEMBL498570 | 0.81 | ALDH1A1 (0.54) | CA1CA2CA12CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110871141-B | Chiral resolution method for simulating magnetic ore dressing and special magnetic enrichment type nano inhibitor thereof | 北京大学 | 2021-01-29 | — | — | CN | claimed |
| CN-110871141-A | Chiral resolution method for simulating magnetic ore dressing and special magnetic enrichment type nano inhibitor thereof | 北京大学 | 2020-03-10 | — | — | CN | claimed |
| US-4533506-A | Resolution of amino acids | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 1985-08-06 | — | — | US | claimed |
| EP-0070114-B1 | A PROCESS FOR PREPARING AN OPTICALLY ACTIVE P-HYDROXYPHENYL-GLYCINE OR A SALT THEREOF | Tanabe Seiyaku Co., Ltd. (JP) | 1985-06-26 | — | — | EP | claimed |
| US-4434107-A | Process for preparing an optically active p-hydroxyphenylglycine or a salt thereof | TANABE SEIYAKU CO., LTD. (JP) | 1984-02-28 | — | — | US | claimed |
| EP-0070114-A1 | A process for preparing an optically active p-hydroxyphenyl-glycine or a salt thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1983-01-19 | — | — | EP | claimed |
| US-3994962-A | INTERMEDIATE FOR PENICILLIN AND CEPHALOSPORIN DERIVATIVES | NIPPON KAYAKU KABUSHIKI KAISHA (JA) | 1976-11-30 | — | — | US | claimed |
| JP-52093741-A | — | — | None | — | — | JP | disclosed |
| US-12104022-B2 | Chiral resolution method mimicking magnetic beneficiation and the magnetic nano-inhibitors for selective enrichment | PEKING UNIVERSITY (CN) | 2024-10-01 | — | — | US | disclosed |
| US-20210163695-A1 | A CHIRAL RESOLUTION METHOD MIMICKING MAGNETIC BENEFICIATION AND THE MAGNETIC NANO-INHIBITORS FOR SELECTIVE ENRICHMENT | PEKING UNIVERSITY (CN) | 2021-06-03 | — | — | US | disclosed |
| CN-110871141-B | Chiral resolution method for simulating magnetic ore dressing and special magnetic enrichment type nano inhibitor thereof | 北京大学 | 2021-01-29 | — | — | CN | disclosed |
| CN-110871141-A | Chiral resolution method for simulating magnetic ore dressing and special magnetic enrichment type nano inhibitor thereof | 北京大学 | 2020-03-10 | — | — | CN | disclosed |
| EP-0437058-B1 | Formation of hydroxyaromatic ketoacetal from an hydroxyaromatic methylketone and production of 5-(4'-hydroxyphenyl)hydantoin and D-p-hydroxyphenylglycine from 4-hydroxyacetophenone | HOECHST CELANESE CORP (US) | 1995-12-27 | — | — | EP | disclosed |
| US-4434107-A | Process for preparing an optically active p-hydroxyphenylglycine or a salt thereof | TANABE SEIYAKU CO., LTD. (JP) | 1984-02-28 | — | — | US | disclosed |
| US-4390722-A | CRYSTALLIZATION FROM SUPERSATURATED SOLUTION USING AMINO ACID AS AS CRYSTAL INHIBITOR | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 1983-06-28 | — | — | US | disclosed |
| US-4390722-A | CRYSTALLIZATION FROM SUPERSATURATED SOLUTION USING AMINO ACID AS AS CRYSTAL INHIBITOR | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 1983-06-28 | — | — | US | disclosed |
| EP-0070114-A1 | A process for preparing an optically active p-hydroxyphenyl-glycine or a salt thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1983-01-19 | — | — | EP | disclosed |
| US-4309362-A | SEEDING SUPERSATURATED SOLUTION WITH CRYSTAL OF ENANTIOMORPH | TANABE SEIYAKU CO., LTD. (JP) | 1982-01-05 | — | — | US | disclosed |
| JP-S5293741-A | P-HYDROXYPHENYLGLYCINE-SULFONIC ACID DERIVATIVE SALTS | NIPPON KAYAKU CO LTD | 1977-08-06 | — | — | JP | disclosed |
| US-3994962-A | INTERMEDIATE FOR PENICILLIN AND CEPHALOSPORIN DERIVATIVES | NIPPON KAYAKU KABUSHIKI KAISHA (JA) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163695-A1 | A CHIRAL RESOLUTION METHOD MIMICKING MAGNETIC BENEFICIATION AND THE MAGNETIC NANO-INHIBITORS FOR SELECTIVE ENRICHMENT | NES, MSN, NAF1 | CA1 40/4885CA2 323/4885CA12 120/4885 |
| US-12104022-B2 | Chiral resolution method mimicking magnetic beneficiation and the magnetic nano-inhibitors for selective enrichment | NES, ALB, NAF1 | CA1 34/4885CA2 323/4885CA12 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.